三元生物(301206) - 2024 Q4 - 年度业绩预告

Financial Projections - The estimated net profit for 2024 is projected to be between 95 million and 120 million RMB, representing an increase of 61.36% to 103.82% compared to the previous year's profit of 58.87 million RMB[3]. - The net profit after deducting non-recurring gains and losses is expected to be between 92.85 million and 117.85 million RMB, reflecting a growth of 60.97% to 104.31% from last year's figure of 57.68 million RMB[3]. Performance Improvement - The increase in performance is attributed to improved erythritol conversion rates and sales, along with reduced raw material and energy costs[6]. - The cost of raw materials and energy has been effectively reduced, with significant decreases in the procurement prices of corn starch, crystalline fructose, and steam, alongside lower electricity costs due to solar power usage[7]. Product Development - The company has successfully launched a new 10,000-ton production line for allulose, significantly boosting production volume and gross profit, thereby establishing a second flagship product[9]. Market Expansion - The company has implemented a market diversification strategy, expanding into emerging markets such as Southeast Asia, India, the Middle East, and South America, which has led to a substantial increase in erythritol sales[8]. Client Relations - The company has strengthened its communication and collaboration with international clients, customizing new formulas to meet their needs while addressing EU anti-dumping investigations[8]. Financial Reporting - The financial data presented is preliminary and has not yet been audited by the accounting firm, with detailed financial information to be disclosed in the 2024 annual report[10].